Good evening :)
Place Order
Add to Watchlist

Gennex Laboratories Ltd

GENNEX

Gennex Laboratories Ltd

GENNEX
Health CarePharmaceuticals
SmallcapWith a market cap of ₹468 cr, stock is ranked 1,879
High RiskStock is 4.29x as volatile as Nifty
21.000.24% (+0.05)
21.000.24% (+0.05)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹468 cr, stock is ranked 1,879
High RiskStock is 4.29x as volatile as Nifty
Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹468 cr, stock is ranked 1,879
High RiskStock is 4.29x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
31.232.65
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.446.570.51%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Gennex Laboratories Limited is engaged in manufacturing of bulk drugs, intermediates and biotech products. Its product portfolio is spread over various product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.12%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.03% to 0.02%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 42.64%, vs industry avg of 15.28%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue42.0344.6956.5856.6860.1762.5969.5691.62105.89
Raw Materialssubtract24.4126.8836.3136.2035.1841.2348.1458.9882.36
Power & Fuel Costsubtract1.972.262.853.303.013.174.394.67
Employee Costsubtract4.965.556.126.817.216.977.877.79
Selling & Administrative Expensessubtract3.133.014.233.343.443.434.423.29
Operating & Other expensessubtract2.923.882.272.724.651.03-3.91-5.05
Depreciation/Amortizationsubtract0.840.920.981.000.880.790.922.372.16
Interest & Other Itemssubtract0.710.730.790.750.740.881.353.083.07
Taxes & Other Itemssubtract0.400.620.800.691.021.171.453.323.30
EPS0.200.060.170.140.300.300.320.650.66
DPS0.000.000.000.000.000.000.000.000.00
Payout ratio0.000.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Gennex Laboratories Ltd35.572.65
Sun Pharmaceutical Industries Ltd46.316.610.73%
Cipla Ltd30.404.670.84%
Torrent Pharmaceuticals Ltd65.4215.810.87%

Price Comparison

Compare GENNEX with any stock or ETF
Compare GENNEX with any stock or ETF
GENNEX
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Increased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has increased by 2.76%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding18.42%0.00%0.00%0.00%81.58%

Feb 2024

Mar 2024

Jun 2024

Sep 2024

Shareholding History

SepDec '23FebMarJunSep0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

GENNEX has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Dividends

Hmm, looks like data is unavailable here. Please come back after some time
News & Opinions
Corporate
Gennex Laboratories AGM scheduled

Gennex Laboratories announced that the 39th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Gennex Laboratories to hold board meeting

Gennex Laboratories will hold a meeting of the Board of Directors of the Company on 6 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Gennex Laboratories consolidated net profit rises 63.51% in the June 2024 quarter

Net profit of Gennex Laboratories rose 63.51% to Rs 4.66 crore in the quarter ended June 2024 as against Rs 2.85 crore during the previous quarter ended June 2023. Sales rose 71.74% to Rs 28.32 crore in the quarter ended June 2024 as against Rs 16.49 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales28.3216.49 72 OPM %23.6230.93 - PBDT5.964.37 36 PBT5.513.72 48 NP4.662.85 64 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Gennex Laboratories to discuss results

Gennex Laboratories will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Ind Bank Housing Ltd leads losers in ‘B’ group

3 years agoBusiness Standard

Generic Engineering jumps on bagging orders

3 years agoBusiness Standard

Generic Engineering Construction and Projects bags orders worth Rs 102 cr

3 years agoEconomic Times